In this issue of Biotech Frontiers, we focus on an upstart company that’s playing “pharmaceutical moneyball” – like the gritty Oakland A’s did with discarded baseball players, it looks through a new lens to find drugs that other pharma companies have put on the back shelf.
While the overall market continues to ride higher, there are signs beneath the surface that suggest things could begin to turn. Taking lessons from a legendary investor, we look at how to avoid getting caught up in the exuberance.
Right now the bond market is not sending very many distress signals. But if the mood shifts, we could suddenly have many more bonds trading at yields that make them appealing to investors with the appetite for high risk/high reward.
